Educating Pharmacists on the Risks of Strong Opioids With Descriptive and Simulated Experience Risk Formats: A Randomized Controlled Trial.

Objectives. High opioid prescription rates in the United States and Europe suggest miscalibrated risk perceptions among those who prescribe, dispense, and take opioids. Findings from cognitive decision science suggest that risk perceptions and behaviors can differ depending on whether people learn about risks by experience or description. This study investigated effects of a descriptive versus an experience-based risk education format on pharmacists' risk perceptions and counseling behavior in the long-term administration of strong opioids to patients with chronic noncancer pain. Methods. In an exploratory, randomized controlled online trial, 300 German pharmacists were randomly assigned to either a descriptive format (fact box) or a simulated experience format (interactive simulation). Primary Outcome Measures. 1) Objective risk perception, 2) subjective risk perception, and 3) intended and 4) actual counseling behavior. Results. Both risk formats significantly improved pharmacists' objective risk perception, but pharmacists exposed to the fact box estimated the benefit-harm ratio more accurately than those exposed to the simulation. Both formats proved equally effective in adjusting pharmacists' subjective risk perception toward a better recognition of opioids' harms; however, pharmacists receiving the simulation showed a greater change in their actual counseling behavior and higher consistency between their intended and actual counseling than pharmacists receiving the fact box. Conclusion. The simulated experience format was less effective than the descriptive format in improving pharmacists' objective risk perception, equally effective in motivating pharmacists to counsel patients on less risky treatment alternatives and more effective in changing the reported actual counseling behavior. Implications. These exploratory findings provide important insights into the relevance of the description-experience gap for drug safety and raise questions for future research regarding the specific mechanisms at work.

Experiencing the risk of overutilising opioids among patients with chronic non-cancer pain in ambulatory care (ERONA): the protocol of an exploratory, randomised controlled trial.

INTRODUCTION: The US opioid crisis and increasing prescription rates in Europe suggest inappropriate risk perceptions and behaviours of people who prescribe, take or advise on opioids: physicians, patients and pharmacists. Findings from cognitive and decision science in areas other than drug safety suggest that people's risk perception and behaviour can differ depending on whether they learnt about a risk through personal experience or description. Experiencing the risk of overutilising opioids among patients with chronic non-cancer pain in ambulatory care (ERONA) is the first-ever conducted trial that aims at investigating the effects of these two modes of learning on individuals' risk perception and behaviour in the long-term administration of WHO-III opioids in chronic non-cancer pain. METHODS AND ANALYSIS: ERONA-an exploratory, randomised controlled online survey intervention trial with two parallel arms-will examine the opioid-associated risk perception and behaviour of four groups involved in the long-term administration of WHO-III opioids: (1) family physicians, (2) physicians specialised in pain therapy, (3) patients with chronic (≥3 months) non-cancer pain and (4) pharmacists who regularly dispense narcotic substances. Participants will be randomly assigned to one of two online risk education interventions, description based or experiencebased. Both interventions will present the best medical evidence available. Participants will be queried at baseline and after intervention on their risk perception of opioids' benefit-harm ratio, their medical risk literacy and their current/intended risk behaviour (in terms of prescribing, taking or counselling, depending on study group). A follow-up will occur after 9 months, when participants will be queried on their actual risk behaviour. The study was developed by the authors and will be conducted by the market research institution IPSOS Health. ETHICS AND DISSEMINATION: The study was approved by the Institutional Review Board of the Max Planck Institute for Human Development. Results will be disseminated through peer-reviewed journals, conference presentations and social media. TRIAL REGISTRATION NUMBER: DRKS00020358.

Prevalence and safety-relevance of drug-related problems in German community pharmacies.

PURPOSE: The purpose of this study was to assess prevalence and characteristics, including safety-relevance, of drug-related problems (DRPs) detectable in community pharmacy routine service, and to investigate the influence of relevant risk factors. METHODS: Patients in 69 community pharmacies in Berlin were surveyed using a checklist for quality assurance of DRP detection in order to enable quantitative detection. An expert committee assessed the safety-relevance of detected DRPs by use of an algorithm. Logistic regression analysis was applied to investigate the influence of different risk factors. RESULTS: Of the 3040 surveyed patients, 638 (21.0%) were affected by DRPs. Among these, 455 (71.3%) had problems of low, 170 (26.6%) of significant and 13 (2.0%) of high safety-relevance. Significant risk factors identified were self-medication and new medication, especially new prescriptions. Age, gender and the number of dispensed drugs had little influence on occurrence of DRPs. The two major groups of DRPs were therapeutic errors, often correlating with self-medication, and information problems, often correlating with new medications. Drug classes most frequently associated with DRPs were analgesics/NSAID, antibiotics, nasal preparations and cough medications. CONCLUSION: DRPs are frequent among patients in German community pharmacies. Advanced research in this field (DRP-pharmacovigilance) and implementation of methods for quality assurance of pharmaceutical counselling, that is exhaustive DRP detection, may improve the safety of drug therapies significantly. In particular, pharmaceutical counselling is an important instrument for assuring treatment appropriateness and safety of OTC drugs.